The Impact of a 10-Month Synbiotic Intake on eGFR, Uremic Toxins, Oxidative Stress, and Inflammatory Markers in Non-Dialysis Chronic Kidney Disease Patients: A Prospective, Non-Randomized, Placebo-Controlled Study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Synbiotic supplementation showed a trend toward reducing indoxyl sulfate (IS) in advanced chronic kidney disease (CKD) patients over 10 months. However, it did not significantly impact renal function or other markers of inflammation and oxidative stress.
Area Of Science
- Nephrology
- Microbiology
- Gastroenterology
Background
- Chronic kidney disease (CKD) prevalence is rising globally, posing a significant public health challenge.
- CKD is linked to gut microbiota dysbiosis, which can worsen disease progression through uremic toxins, inflammation, and oxidative stress.
- Modulating gut microbiota with synbiotics is a potential therapeutic strategy for CKD.
Purpose Of The Study
- To assess the 10-month impact of synbiotic supplementation versus placebo on estimated glomerular filtration rate (eGFR).
- To evaluate changes in circulating concentrations of indoxyl sulfate (IS), p-cresyl sulfate (p-CS), interleukin-6 (IL-6), and malondialdehyde (MDA).
- To investigate the effects in non-dialysis patients with stage IV-V CKD.
Main Methods
- A single-blind, placebo-controlled trial involving 50 non-dialysis CKD IV-V patients.
- Participants were allocated to receive daily synbiotics (Lactobacillus acidophilus + fructooligosaccharides) or placebo for 10 months.
- Measurements of eGFR, IS, p-CS, IL-6, and MDA were taken at baseline and month 10.
Main Results
- Synbiotic supplementation showed a trend toward a slower decline in eGFR compared to placebo (difference of 2.3 mL/min/1.73 m²).
- A significant reduction in serum IS levels was observed in the synbiotic group versus placebo (-12.3 ng/L difference, p=0.005).
- No significant differences were found for p-CS, IL-6, or MDA levels between groups after adjustment.
Conclusions
- Ten months of synbiotic supplementation may help reduce serum IS levels in advanced CKD patients.
- The study suggests potential benefits of microbiota-targeted therapies for CKD.
- Larger studies are needed to confirm these findings and explore long-term effects on renal function and other markers.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...